{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.30 vs. cons $1.28",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Comparable sales growth",
      "prediction": "MISS",
      "answer": "pred ~9.6% vs. cons 9.85%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FreeStyle Libre/CGM comparable growth",
      "prediction": "BEAT",
      "answer": "pred ~11.5% vs. cons 11.0%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$5.48 midpoint vs. cons $5.50 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Comparable sales-growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.0% midpoint vs. cons 7.0% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.9,
  "day5_path": "FADE",
  "day5_rationale": "A ~$0.02 Q2 EPS beat is unlikely to flow through because FY2026 EPS guidance of ~$5.48 remains below consensus of $5.50, implying second-half EPS of roughly $3.03 versus Street expectations near $3.05; improving Libre and Nutrition trends support an initial relief rally, but limited upward revisions drive a partial fade.",
  "day5_confidence": "MEDIUM"
}